Bionor Pharma – Preliminary result of the rights issue
(Oslo, Norway, 30 September 2016) Reference is made to previous stock exchange announcements and the prospectus (the “Prospectus”) dated 14 September 2016 concerning the rights issue (the “Rights Issue”) of 525,000,000 new shares at a subscription price of NOK 0.10 per share in Bionor Pharma ASA (“Bionor” or the “Company”, ticker “BIONOR”).
STOCK EXCHANGE ANNOUNCEMENT
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES
The subscription period of the Rights Issue expired 29 September 2016 at 16:30 CET. A preliminary counting of the subscriptions indicates that approximately 1,126 million shares have been subscribed out of a total of 525 million shares available, i.e. an oversubscription of approximately 114.5%. The gross proceeds from the Rights Issue will be NOK 52.5 million. Allocation of shares in the Rights Issue will be resolved on or about 4 October 2016 by the Board of Directors of Bionor in accordance with the allocation criteria set out in the Prospectus. The final result of the Rights Issue is expected to be published on or about 4 October 2016. Letters of allocation will be distributed to investors giving notification of allocated new shares and the corresponding amount to be paid by each subscriber.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Unni Hjelmaas, Acting CEO, +47 915 19 651, firstname.lastname@example.org
Jens Krøis, CFO, +45 208 01 668, email@example.com
Link to announcement in pdf